

Reference list

- 1 Harding, R. E., Barton, T., Niepceron, M., Harris, E., Bennett, E., Gent, E., ... & Morgan, C. J. (2025). The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. *Addiction*.
- 2 Tarpanian, B., (2025) Understanding ketamine use in Blackpool: A qualitative study of life transitions and social contexts (Unpublished Thesis, MSc Public Health: Liverpool John Moores University)
- 3 Collins, A., Coughlin, D., Miller, J., & Kirk, S. (2015). The production of quick scoping reviews and rapid evidence assessments: A how to guide.
- 4 Janssen-Aguilar, R., Meshkat, S., Demchenko, I., Zhang, Y., Greenshaw, A., Dunn, W., ... & Bhat, V. (2025). Role of ketamine in the treatment of substance use disorders: A systematic review. *Journal of Substance Use and Addiction Treatment*, 209705.
- 5 Moore, E., Mayes, R., Harkin, M., Miller, J. L., & Johnson, P. N. (2021). Extended duration ketamine infusions in critically ill children: a case report and review of the literature. *Journal of Pediatric Intensive Care*, 10(03), 221-227.
- 6 Usman, M. A. (2023). Should ketamine not be banned? A scoping review. *Disaster medicine and public health preparedness*, 17, e47.
- 7 Chaves, T. V., Wilffert, B., & Sanchez, Z. M. (2023). Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. *The American Journal of Drug and Alcohol Abuse*, 49(2), 141-150.
- 8 Schep, L. J., Slaughter, R. J., Watts, M., Mackenzie, E., & Gee, P. (2023). The clinical toxicology of ketamine. *Clinical Toxicology*, 61(6), 415-428.
- 9 Roncero, C., Merizalde-Torres, M., Szerman, N., Torrens, M., Vega, P., Andres-Olivera, P., & Javier Álvarez, F. (2025). Is there a risk of esketamine misuse in clinical practice?. *Therapeutic Advances in Drug Safety*, 16, 20420986241310685.
- 10 Carroll, A., Bayes, A., Montebello, M., Brett, J., Arunogiri, S., Saunders, J. B., & Loo, C. K. (2024). Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand. *Australian & New Zealand Journal of Psychiatry*, 58(10), 831-838.
- 11 Chaudhari, R., Nikam, M., Bharwad, K., Khatode, O., Thorat, A., & Bhabad, P. (2025). Ketamine in Modern Medicine: Antidepressant Breakthrough, Anesthetic Staple, or Substance of Misuse. *International Journal of Scientific Research and Technology*.
- 12 Johnston, J. N., Henter, I. D., & Zarate Jr, C. A. (2023). The antidepressant actions of ketamine and its enantiomers. *Pharmacology & therapeutics*, 246, 108431.
- 13 Smith-Apeladoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022). Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. *The Lancet Psychiatry*, 9(11), 907-921.
- 14 Kalmoe, M. C., Janski, A. M., Zorumski, C. F., Nagele, P., Palanca, B. J., & Conway, C. R. (2020). Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents. *Journal of the neurological sciences*, 412, 116778.
- 15 Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate Jr, C. A. (2024). Ketamine in neuropsychiatric disorders: an update. *Neuropsychopharmacology*, 49(1), 23-40.
- 16 Rathore, B. S., Singh, S., Gupta, M., & Verma, P. (2025). Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review. *The American Journal of Drug and Alcohol Abuse*, 51(5), 563-576.
- 17 Riccardi, A., Guarino, M., Serra, S., Spampinato, M. D., Vanni, S., Shiffer, D., ... & De Iaco, F. (2023). Narrative review: low-dose ketamine for pain management. *Journal of clinical medicine*, 12(9), 3256.
- 18 Gautam, C. S., Mahajan, S. S., Sharma, J., Singh, H., & Singh, J. (2020). Repurposing potential of ketamine: opportunities and challenges. *Indian journal of psychological medicine*, 42(1), 22-29.
- 19 Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022). Long-term safety of ketamine and esketamine in treatment of depression. *Expert opinion on drug safety*, 21(6), 777-787.
- 20 Keeler, J. L., Treasure, J., Juruena, M. F., Kan, C., & Himmerich, H. (2021). Ketamine as a treatment for anorexia nervosa: a narrative review. *Nutrients*, 13(11), 4158.

- 21 Pulcu, E., Guinea, C., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2022). A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings. *Molecular Psychiatry*, 27(1), 81-87.
- 22 Evers, A. G., Murrough, J. W., Charney, D. S., & Costi, S. (2022). Ketamine as a prophylactic resilience-enhancing agent. *Frontiers in psychiatry*, 13, 833259.
- 23 Courtes, A. C., Jones, G. H., Henter, I. D., Shahani, L., Fries, G. R., Juruena, M. F., ... & Machado-Vieira, R. (2025). Blood-based biomarkers in ketamine treatment: A blueprint for translational drug development in mood disorders. *Journal of Affective Disorders*, 120016.
- 24 Waheed, H. W., Ashraf, M. R., Talha, S., Hanzala, J., Iqra, B., Ahmad, Z., ... & Allah, D. (2025). Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions. *Cureus*, 17(5).
- 25 Beerten, S. G., Matheï, C., & Aertgeerts, B. (2023). Ketamine misuse: an update for primary care. *The British Journal of General Practice*, 73(727), 87.
- 26 Jilka, S., Odoi, C. M., Wilson, E., Meran, S., Simblett, S., & Wykes, T. (2021). Ketamine treatment for depression: qualitative study exploring patient views. *BJPsych Open*, 7(1), e32.
- 27 Lascelles, K., Marzano, L., Brand, F., Trueman, H., McShane, R., & Hawton, K. (2021). Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences. *BJPsych Open*, 7(1), e9.
- 28 Guerrini, I., Kalk, N., Jelen, L., & Strang, J. (2025). Non-prescribed ketamine use is rising in the UK. *bmj*, 389.
- 29 Strous, J. F., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., ... & Figee, M. (2022). Brain changes associated with long-term ketamine abuse, a systematic review. *Frontiers in neuroanatomy*, 16, 795231.
- 30 Lomas, C. (2025). Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction. *Journal of Addictive Diseases*, 1-22.
- 31 Hom, B., McIntee, D., Zhang, Y. P., Hershenhouse, J. S., Nash, A., & Richeimer, S. (2025). Evaluating oral ketamine's adverse side effects in chronic pain patients. *Saudi Journal of Anaesthesia*, 19(4), 546-552.
- 32 Castellani, D. (2022). Ketamine Misuse and Adverse Body Effects: A Focus on Uropathy. In *Handbook of Substance Misuse and Addictions: From Biology to Public Health* (pp. 1-24). Cham: Springer International Publishing.
- 33 Harding, R. E., Barton, T., Niepceron, M., Harris, E., Bennett, E., Gent, E., ... & Morgan, C. J. (2025). The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. *Addiction*.
- 34 Andrade, C. (2025). Ketamine-Associated Uropathy During Therapeutic and Nontherapeutic Use. *J Clin Psychiatry*, 86(4), 25f16083.
- 35 Van Amsterdam, J., & Van Den Brink, W. (2022). Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. *Expert Opinion on Drug Safety*, 21(1), 83-94.
- 36 Strous, J. F., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., ... & Figee, M. (2022). Brain changes associated with long-term ketamine abuse, a systematic review. *Frontiers in neuroanatomy*, 16, 795231.
- 37 Harding, R. E., Barton, T., Niepceron, M., Harris, E., Bennett, E., Gent, E., ... & Morgan, C. J. (2025). The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options. *Addiction*.
- 38 Andrade, C. (2025). Ketamine-Associated Uropathy During Therapeutic and Nontherapeutic Use. *J Clin Psychiatry*, 86(4), 25f16083.
- 39 McKnight, R., & Horgan, P. (2024). An Interdisciplinary Approach to the Management of Ketamine Induced Uropathy. *BJPsych Open*, 10(S1), S283-S284.
- 40 Abdelrahman, A., & Belal, M. (2025). Rare but relevant: Ketamine-induced cystitis—an in-depth review for addiction medicine. *Addiction*.
- 41 Chun, J., Kotha, S., Nayagam, J., Gallaher, C., Miquel, R., Hong, S. M., ... & Zen, Y. (2025). Ketamine cholangiopathy: clinical features and liver biopsy findings. *Histopathology*, 87(1), 130-137.
- 42 Vanrusselt, A., Nijs, J., Van den Bergh, L., Schoofs, N., Smets, S., Strybol, D., & Rappaport, A. (2025). Ketamine-induced sclerosing cholangitis: a case series. *Acta gastro-enterologica Belgica*, 88(3).

- 43 Marongiu, S., van Eijk, M., Gresnigt, F. M., Croes, E. A., & Franssen, E. J. (2025). Rising incidence of recreational ketamine use: Clinical cases and management in emergency settings. *Toxicology Reports*, 14, 101940.
- 44 Hervé, F., Aronsson, P., Ochoa, D. C., Van Koeveringe, G., Mosiello, G., Averbeck, M. A., ... & Abrams, P. (2025). Can We Better Understand, Diagnose, and Treat Ketamine-Induced Uropathy, and Can It Be Reversed? ICI-RS 2024. *Neurourology and Urodynamics*, 44(3), 548-557.
- 45 Castellani, D. (2022). Ketamine Misuse and Adverse Body Effects: A Focus on Uropathy. In *Handbook of Substance Misuse and Addictions: From Biology to Public Health* (pp. 1-24). Cham: Springer International Publishing.
- 46 Strous, J. F., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., ... & Figee, M. (2022). Brain changes associated with long-term ketamine abuse, a systematic review. *Frontiers in neuroanatomy*, 16, 795231.
- 47 Henderson, F. J. H., Hill, S. L., & Thomas, S. H. L. (2024). Drug misuse. *Medicine*.
- 48 Vari, M. R., Ricci, G., Cavallo, M., Pichini, S., Sirignano, A., & Graziano, S. (2022). Ketamine: from prescription anaesthetic to a new psychoactive substance. *Current Pharmaceutical Design*, 28(15), 1213-1220.
- 49 Belal, M., Downey, A., Doherty, R., Ali, A., Hashim, H., Kozan, A., ... & BAUS Section of Female, Neurological and Urodynamic Urology. (2024). British Association of Urological Surgeons Consensus statements on the management of ketamine uropathy. *BJU international*, 134(2), 148-154.
- 50 Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Di Vincenzo, J. D., Jaber, S., ... & McIntyre, R. S. (2022). The abuse liability of ketamine: A scoping review of preclinical and clinical studies. *Journal of psychiatric research*, 151, 476-496.
- 51 Castellani, D., Pirola, G. M., Gubbiotti, M., Rubilotta, E., Gudar, K., Gregori, A., & Dellabella, M. (2020). What urologists need to know about ketamine-induced uropathy: a systematic review. *Neurourology and Urodynamics*, 39(4), 1049-1062.
- 52 Michienzi, A. E., & Borek, H. A. (2022). Emerging agents of substance use/misuse. *Emergency Medicine Clinics*, 40(2), 265-281.
- 53 Simonetti, A., Trimble, A., Shrock, H., Gudi, R., & Murthy, V. (2023). Effect of Prenatal Ketamine Exposure: A Focused Literature Review.
- 54 Edinoff, A. N., Sall, S., Koontz, C. B., Williams, A. K., Drumgo, D., Mouhaffel, A., ... & Kaye, A. D. (2023). Ketamine evolving clinical roles and potential effects with cognitive, motor and driving ability. *Neurology international*, 15(1), 352-361.
- 55 Bourillon, A., Cornu, J. N., Herve, F., Pangui, R., Thuillier, C., Doizi, S., ... & Peyronnet, B. (2024). Management of ketamine cystitis: National guidelines from the French Association of Urology (CUROPF/CTMH). *The French Journal of Urology*, 34(14), 102754.
- 56 Hottat, A., & Hantson, P. (2023). Toxicity patterns associated with chronic ketamine exposure. *Toxicologie Analytique et Clinique*, 35(2), 113-123.
- 57 Ng, S. H., Lee, Y. Z., Hong, M. Y., Kow, A. S. F., d'Arqom, A., Tham, C. L., ... & Lee, M. T. (2025). Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review. *Current Reviews in Clinical and Experimental Pharmacology*.
- 58 McIntyre, R. S., Mansur, R. B., Rosenblatt, J. D., Teopiz, K. M., & Kwan, A. T. (2025). The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS). *Expert Opinion on Drug Safety*, 24(8), 909-914.
- 59 Schifano, F., Corkery, J., Oyefeso, A., Tonia, T., & Ghodse, A. H. (2008). Trapped in the "K-hole": overview of deaths associated with ketamine misuse in the UK (1993-2006). *Journal of clinical psychopharmacology*, 28(1), 114-116.
- 60 Plöderl, M., Cooper, R., Walker, T., Shah, V., Horowitz, M., Volkmann, C., & Moncrieff, J. (2025). Effects of ketamine and esketamine on death, suicidal behaviour, and suicidal ideation in psychiatric disorders: A systematic review and meta-analysis. *medRxiv*, 2025-08.
- 61 Katsiari, T., Bae, Y. E., Darlington Carbin Joseph, D., Abou Chedid, W., Moschonas, D., Kusuma, V. R. M., ... & Perry, M. J. A. (2024). Newer therapies and surgical management of ketamine-induced uropathy: A review. *Urologia Journal*, 91(1), 199-206.
- 62 McKnight, R., Chibuzo, I., Myton, T., & Lee, L. (2025). Optimizing Care for Ketamine Use Disorder: An Interdisciplinary Treatment Model. *BJPsych Open*, 11(S1), S146-S147.

- 63 Corkery, J. M., Hung, W. C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021). Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. *Journal of psychopharmacology*, 35(11), 1324-1348.
- 64 Schifano, N., Chiappini, S., Castiglione, F., Salonia, A., & Schifano, F. (2021). Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. *LUTS: Lower Urinary Tract Symptoms*, 13(2), 230-237.
- 65 Shkoukani, Z. W., Gopi, P., Tate, L., Calmuc, A., Omar, A., Abdulmajed, M. I., & Abdulmajed, M. (2025). Ketamine-Induced Uropathy in a High-Prevalence Region: Knowledge, Diagnostic Practices, and Treatment Patterns Among Primary and Secondary Care Providers. *Cureus*, 17(6).
- 66 Short, B., Dong, V., Galvez, V., Vulovic, V., Martin, D., Bayes, A. J., ... & Loo, C. K. (2020). Development of the ketamine side effect tool (KSET). *Journal of affective disorders*, 266, 615-620.
- 67 Sturgess, G., Beckley, I., Shepherd, R., & Downey, A. (2023). Ketamine uropathy: Clinical experience in a high prevalence center. *Neurourology and Urodynamics*, 42(7), 1555-1562.
- 68 Akintimehin, A. O., & Hoare, J. (2025). "K-cramps": ketamine misuse and abdominal pain. *Frontline Gastroenterology*.
- 69 Juruena, M. F., & Young, A. H. (2025). Ketamine: Therapeutic potential versus recreational misuse. *Journal of Psychopharmacology*, 39(1), 3-4.
- 70 Okunlola, A. O., Sufrian, S., Ajao, T. O., Uzzaman, G. R., & Fernandez, C. J. (2024). Multi-organ Failure in a Patient With Chronic Ketamine Use: A Case Report. *Cureus*, 16(11).
- 71 Ricci, V., De Berardis, D., Shoib, S., Martinotti, G., & Maina, G. (2025). Psychotic-Like Experiences in Young Recreational Users of Ketamine: A Case Study. *Journal of psychoactive drugs*, 1-10.
- 72 Li, Y., Dong, Z., Wen, G., Ren, X., Ren, W., Yan, L., ... & Wu, X. (2021). Long-term ketamine administration induces bladder damage and upregulates autophagy-associated proteins in bladder smooth muscle tissue. *Environmental Toxicology*, 36(12), 2521-2529.
- 73 Chu, P. S. K., Ma, W. K., Wong, S. C. W., Chu, R. W. H., Cheng, C. H., Wong, S., ... & Man, C. W. (2008). The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. *BJU international*, 102(11), 1616-1622.
- 74 Jhang, J. F., Hsu, Y. H., & Kuo, H. C. (2015). Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. *International Journal of Urology*, 22(9), 816-825.
- 75 Chun, J., Kotha, S., Nayagam, J., Gallaher, C., Miquel, R., Hong, S. M., ... & Zen, Y. (2025). Ketamine cholangiopathy: clinical features and liver biopsy findings. *Histopathology*, 87(1), 130-137.
- 76 Hervé, F., Aronsson, P., Ochoa, D. C., Van Koeveringe, G., Mosiello, G., Averbeck, M. A., ... & Abrams, P. (2025). Can We Better Understand, Diagnose, and Treat Ketamine-Induced Uropathy, and Can It Be Reversed? ICI-RS 2024. *Neurourology and Urodynamics*, 44(3), 548-557.
- 77 Chaves, T. V., Wilffert, B., & Sanchez, Z. M. (2023). Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. *The American Journal of Drug and Alcohol Abuse*, 49(2), 141-150.
- 78 Deng, L., Wu, L., Gao, R., Xu, X., Chen, C., & Liu, J. (2023). Non-opioid anesthetics addiction: a review of current situation and mechanism. *Brain Sciences*, 13(9), 1259.
- 79 Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021). Substance-induced psychoses: an updated literature review. *Front Psychiatry*. 2021; 12: 694863. Very important because it is updated literature review.
- 80 Van Amsterdam, J., & Van Den Brink, W. (2022). Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. *Expert Opinion on Drug Safety*, 21(1), 83-94.
- 81 Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2025). Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature. *Journal of Psychopharmacology*, 39(1), 49-65.
- 82 Li, S. W., Kumpf, K. T., Urrutia, J., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2025). Ketamine for depression, but at what cost? a review of ketamine's neurotoxic effects from preclinical and human studies. *American Journal of Psychiatry*, 182(10), 903-912.

- 83 Barrios, K. P., Connolly, D. J., Ferris, J. A., Maier, L. J., Barratt, M. J., Winstock, A. R., ... & Gilchrist, G. (2025). Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment. *Journal of Psychopharmacology*, 39(1), 8-22.
- 84 Yang, K. H., Kepner, W., Cleland, C. M., & Palamar, J. J. (2025). Trends and characteristics in ketamine use among US adults with and without depression, 2015–2022. *Journal of Affective Disorders*, 373, 345-352.
- 85 Palamar, J. J. (2025). Trends in ketamine use among nightclub attendees in New York City, 2017–2024. *International Journal of Drug Policy*, 140, 104825.
- 86 Gladstones Clinic. (2024, March 1). The biological effects of ketamine abuse. <https://gladstonesclinic.com/blog/addiction-news/biological-effects-ketamine-abuse/>
- 87 Office for Health Improvement and Disparities. (2024a). Young people’s substance misuse treatment statistics 2022 to 2023: Report. <https://www.gov.uk/government/statistics/substance-misuse-treatment-for-young-people-2022-to-2023/young-peoples-substance-misuse-treatment-statistics-2022-to-2023-report>
- 88 Office for Health Improvement and Disparities. (2024b). Children and young people’s substance misuse treatment statistics 2023 to 2024: Report. <https://www.gov.uk/government/statistics/substance-misuse-treatment-for-young-people-2023-to-2024/children-and-young-peoples-substance-misuse-treatment-statistics-2023-to-2024-report>
- 89 Gladstones Clinic. (2023, September 28). Ketamine and increased prevalence within substance misuse. <https://gladstonesclinic.com/blog/addiction-news/ketamine-increased-prevalence-substance-misuse/>
- 90 Manchester Metropolitan University. (2024, October 5). GM TRENDS 2023–24 ketamine supplement. <https://gmtrends.mmu.ac.uk/wp-content/uploads/sites/425/2024/10/GM-TRENDS-2023-24-ketamine.pdf>
- 91 Hancorn, G. (2025, June 25). Ketamine crisis ‘overwhelming’ authorities as teens dealing and taking Class B drug. *ITV News*. <https://www.itv.com/news/2025-06-25/ketamine-overwhelming-authorities-as-teens-dealing-and-taking-class-b-drug>
- 92 Alder Hey Children’s NHS Foundation Trust. (2025, July 2). Alder Hey opens the first NHS ketamine clinic for children and young people in the UK. <https://www.alderhey.nhs.uk/alder-hey-opens-the-first-nhs-ketamine-clinic-for-children-and-young-people-in-the-uk/>
- 93 BBC News. (2025) Generation K: The disturbing rise of ketamine abuse among young people. <https://www.bbc.co.uk/news/articles/c5y0g2gnjrqo>
- 94 The Guardian. (2025, January 13). Ketamine move from club to chill-out drug troubling culture shift. <https://www.theguardian.com/society/2025/jan/13/ketamine-move-club-to-chill-out-drug-troubling-culture-shift>
- 95 The Guardian. (2025, January 7). Home Office may reclassify ketamine in response to record levels of use. <https://www.theguardian.com/society/2025/jan/07/home-office-may-reclassify-ketamine-in-response-to-record-levels-of-use>
- 96 The Guardian. (2024, November 5). The agony of ketamine addiction: ‘I felt like I was peeing glass’. <https://www.theguardian.com/society/2024/nov/05/the-agony-of-ketamine-addiction-i-felt-like-i-was-peeing-glass>
- 97 The Guardian. (2024, September 16). Young people addicted to ketamine a national problem, says UK expert. <https://www.theguardian.com/society/2024/sep/16/young-people-addicted-to-ketamine-a-national-problem-says-uk-expert>
- 98 The Guardian. (2024, November 7). The ketamine crisis has crept up on British youth. <https://www.theguardian.com/society/2024/nov/07/the-ketamine-crisis-has-crept-up-on-british-youth>
- 99 The Guardian. (2024, January 5). Matthew Perry death, ketamine therapy and mental health. <https://www.theguardian.com/tv-and-radio/2024/jan/05/matthew-perry-death-ketamine-therapy-mental-health>
- 100 Marongiu, S., van Eijk, M., Gresnigt, F. M., Croes, E. A., & Franssen, E. J. (2025). Rising incidence of recreational ketamine use: Clinical cases and management in emergency settings. *Toxicology Reports*, 14, 101940.
- 101 Charoensakulchai, S., Onwan, M., Kanchanasurakit, S., Flaherty, G., & Matsee, W. (2024). Recreational substance use among international travellers. *Journal of travel medicine*, 31(4), taae012.

- 102 Castellani, D. (2022). Ketamine Misuse and Adverse Body Effects: A Focus on Urography. In Handbook of Substance Misuse and Addictions: From Biology to Public Health (pp. 1-24). Cham: Springer International Publishing.
- 103 Charoensakulchai, S., Onwan, M., Kanchanasurakit, S., Flaherty, G., & Matsee, W. (2024). Recreational substance use among international travellers. *Journal of travel medicine*, 31(4), taee012.
- 104 Isba, R., Brewster, L., Lunn, J., & Corbett, H. (2025). Non-prescribed ketamine use is rising in the UK—including among under 16s. *bmj*, 390.
- 105 Monarque, M., Sabetti, J., & Ferrari, M. (2023). Digital interventions for substance use disorders in young people: rapid review. *Substance abuse treatment, prevention, and policy*, 18(1), 13.
- 106 Deng, L., Wu, L., Gao, R., Xu, X., Chen, C., & Liu, J. (2023). Non-opioid anesthetics addiction: a review of current situation and mechanism. *Brain Sciences*, 13(9), 1259.
- 107 Roberts, E., Sanderson, E., & Guerrini, I. (2024). The pharmacological management of ketamine use disorder: a systematic review. *Journal of Addiction Medicine*, 18(5), 574-579.
- 108 Verma, R., Colley, T., Waldock, C., Bird, L., & Guerrini, I. (2024). Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review. *Journal of Addiction Medicine*, 10-1097.
- 109 Ralphs, R., Day, J., & Dewhurst, J. (2025). Commentary on Harding et al.: Responding to ketamine use disorder—Integrating practice, research, and whole-system approaches to harm reduction. *Addiction (Abingdon, England)*, 120(10), 1980.
- 110 Humphreys, K., Todd Korthuis, P., Stjepanović, D., & Hall, W. (2025). Therapeutic potential of psychedelic drugs: navigating high hopes, strong claims, weak evidence, and big money. *Annual review of psychology*, 76(1), 143-165.
- 111 Sumnall, H. (2023). Is it possible to reduce population levels of illegal drugs use?. *bmj*, 383.
- 112 Harris, S. K., Knight, J. R., Van Hook, S., Sherritt, L., Brooks, T. L., Kulig, J. W., Nordt, C. A., & Saitz, R. (2016). Adolescent substance use screening in primary care: Validity of computer self-administered versus clinician-administered screening. *Substance Abuse*, 37(1), 197–203. <https://doi.org/10.1080/08897077.2015.1015706> (PMCID: PMC4573375)
- 113 Knight, J. R., Sherritt, L., Gibson, E. B., Levinson, J. A., Grubb, L. K., Samuels, R. C., Silva, T., Vernacchio, L., Wornham, W., & Harris, S. K. (2019). Effect of computer-based substance use screening and brief behavioral counseling vs usual care for youths in pediatric primary care: A pilot randomized clinical trial. *JAMA Network Open*, 2(6), e196258. <https://doi.org/10.1001/jamanetworkopen.2019.6258> (PMCID: PMC6593643)
- 114 Pfarrwaller, E., Meynard, A., Reyre, A., Sommer, J., & Haller, D. M. (2019). Excessive substance use screening to encourage behaviour change among young people in primary care: Pilot study in preparation for a randomized trial. *Addictive behaviors*, 98, 106049. <https://doi.org/10.1016/j.addbeh.2019.106050>
- 115 Huang, S.-F., Zheng, W.-L., Liao, J.-Y., Huang, C.-M., Lin, T.-Y., & Guo, J.-L. (2018). The effectiveness of a theory-based drama intervention in preventing illegal drug use among students aged 14–15 years in Taiwan. *Health Education Journal*, 77(4), 470-481. <https://doi.org/10.1177/0017896918768647>
- 116 Hecht, M. L., Corman, S. R., & Miller-Rassulo, M. (1993). An Evaluation of the Drug Resistance Project: A Comparison of Film Versus Live Performance Media. *Health Communication*, 5(2), 75–88. https://doi.org/10.1207/s15327027hc0502_1
- 117 Quek, L.-H., White, A., Low, C., Brown, J., Dalton, N., Dow, D., & Connor, J. P. (2012). Good choices, great future: An applied theatre prevention program to reduce alcohol-related risky behaviours during Schoolies. *Drug and Alcohol Review*, 31(7), 897–902. <https://doi.org/10.1111/j.1465-3362.2012.00453.x>
- 118 Shrand, J., DiGiovanni, M., Lee, D., Kishore, A., & Martin, A. (2021). *Drug Story Theater: A mixed-methods study of a peer-to-peer approach to substance abuse education*. *Health Behavior and Policy Review*, 8(4), 281–293. <https://doi.org/10.14485/HBPR.8.4.2>
- 119 Stephens-Hernandez, A. B., Livingston, J. N., Dacons-Brock, K., Craft, H. L., Cameron, A., Franklin, S. O., & Howlett, A. C. (2007). Drama-based education to motivate participation in substance abuse prevention. *Substance abuse treatment, prevention, and policy*, 2, 11. <https://doi.org/10.1186/1747-597X-2-12>
- 120 Kewley, S., & Van Hout, M. C. (2022). “I’d probably be dead now”: Evaluating the impact of theatre practitioners working on a recovery-based community drama project. *International*

- Journal of Mental Health and Addiction, 20(2), 1212–1230. <https://doi.org/10.1007/s11469-020-00437-4>
- 121 Warren, J. R., Hecht, M. L., Wagstaff, D. A., Elek, E., Ndiaye, K., Dustman, P., & Marsiglia, F. F. (2006). Communicating Prevention: The Effects of the <i>keepin' it REAL</i> Classroom Videotapes and Televised PSAs on Middle-School Students' Substance Use. *Journal of Applied Communication Research*, 34(2), 209–227. <https://doi.org/10.1080/00909880600574153>
 - 122 Bonyani, A., Safaeian, L., Chehrazhi, M., Etedali, A., Zaghian, M., & Mashhadian, F. (2018). A high school-based education concerning drug abuse prevention. *Journal of education and health promotion*, 7, 88. https://doi.org/10.4103/jehp.jehp_122_18
 - 123 Nair, V., Gaffney, H., Jolliffe, D., & White, H. (2023). Functional Family Therapy (FFT): YEF Toolkit technical report. Youth Endowment Fund. https://youthendowmentfund.org.uk/wp-content/uploads/2023/12/YEF-Functional-Family-Therapy-Technical-Report_December-2023-2.pdf
 - 124 Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D., & Bagley, S. M. (2021). Integrating harm reduction into outpatient opioid use disorder treatment settings. *Journal of General Internal Medicine*, 36(12), 3810–3819. <https://doi.org/10.1007/s11606-021-06904-5>
 - 125 Rath, J. M., Perks, S. N., Vallone, D. M., Barton, A. A., Stephens, D. K., Simard, B., & Hair, E. C. (2021). Educating Young Adults about Opioid Misuse: Evidence from a Mass Media Intervention. *International journal of environmental research and public health*, 19(1), 22. <https://doi.org/10.3390/ijerph19010022>
 - 126 McNabb, C., and Purcell, R., (2009). Motivational interviewing: Young people with substance use and mental health disorders. National Youth Mental Health Foundation.
 - 127 Ghatti, C., Chen, X. J., Brenner, A. K., Hakvoort, L. G., Lien, L., Fachner, J., & Gold, C. (2022). Music therapy for people with substance use disorders. The Cochrane database of systematic reviews, 5(5), CD012576. <https://doi.org/10.1002/14651858.CD012576.pub3>
 - 128 Dingle, G. A., Gleadhill, L., & Baker, F. A. (2008). Can music therapy engage patients in group cognitive behaviour therapy for substance abuse treatment?. *Drug and alcohol review*, 27(2), 190–196. <https://doi.org/10.1080/09595230701829371>
 - 129 Smith, E., Carter, M., Walklet, E., & Hazell, P. (2023). Investigating recovery from problem substance use using digital Photovoice. *Journal of Community Psychology*, 51, 1378–1393. <https://doi.org/10.1002/jcop.22958>
 - 130 Brazg, T., Bekemeier, B., Spigner, C., & Huebner, C. E. (2011). Our community in focus: the use of photovoice for youth-driven substance abuse assessment and health promotion. *Health promotion practice*, 12(4), 502–511. <https://doi.org/10.1177/1524839909358659>
 - 131 Salerno Valdez, E., Korchmaros, J., Sabo, S., Garcia, D. O., Carvajal, S., & Stevens, S. (2019). How the U.S.-Mexico border influences adolescent substance use: Youth participatory action research using photovoice. *The International journal on drug policy*, 73, 146–155. <https://doi.org/10.1016/j.drugpo.2019.07.012>
 - 132 Goodyear, T., Barborini, C., Gilmore, R., Collin-Gray, A., Jensen, M., Young, L., Hossain, A., He, E., & Other Members of the Substance Use Beyond the Binary Youth Action Committee (2025). Harm reduction in photovoice knowledge mobilization with 2S/LGBTQ+ youth who use(d) drugs: A community showcase. *Harm reduction journal*, 22(1), 109. <https://doi.org/10.1186/s12954-025-01263-3>
 - 133 Hashemi, R., & Vogel, E. A. (2024). Adolescents' perceptions of substance use messaging in the age of social media: resolving cognitive dissonance. *Health education research*, 39(1), 1–11. <https://doi.org/10.1093/her/cyad046>
 - 134 Miller-Day, M., & Hecht, M. L. (2013). Narrative means to preventative ends: a narrative engagement framework for designing prevention interventions. *Health communication*, 28(7), 657–670. <https://doi.org/10.1080/10410236.2012.762861>
 - 135 Hamm, M., Wilson, J. D., Lee, Y. J., Norman, N., Winstanley, E. L., & McTigue, K. M. (2024). Substance use as subtext to health narratives: Identifying opportunities for improving care from community member perspectives. *Patient education and counseling*, 128, 108384. <https://doi.org/10.1016/j.pec.2024.108384>
 - 136 Sanchez RP, Bartel CM. The Feasibility and Acceptability of "Arise": An Online Substance Abuse Relapse Prevention Program. *Games Health J*. 2015 Apr;4(2):136-44. doi: 10.1089/g4h.2014.0015. Epub 2014 Oct 27. PMID: 26181807; PMCID: PMC4601551.

- 137 Abroms, L. C., Leavitt, L. E., Van Alstyne, J. M., Schindler-Ruwisch, J. M., Fishman, M. J., & Greenberg, D. (2015). A Motion Videogame for Opioid Relapse Prevention. *Games for health journal*, 4(6), 494–501. <https://doi.org/10.1089/g4h.2014.0100>
- 138 Man DWK. Virtual reality-based cognitive training for drug abusers: A randomised controlled trial. *Neuropsychol Rehabil*. 2020 Mar;30(2):315-332. doi: 10.1080/09602011.2018.1468271. Epub 2018 May 8. PMID: 29734923.
- 139 Banerjee, S. C., & Greene, K. (2013). "Yo! This is no lie, if you smoke, you die": a content analysis of anti-smoking posters created by adolescents. *Journal of substance use*, 18(2), 119–128. <https://doi.org/10.3109/14659891.2011.615886>
- 140 Stewart, John E. and Wagner-Greene, Victoria () "Amplifying Voices in the Midst of a Substance Use Crisis: StoryVisual Approach," *The RAISE Center Journal*: Vol. 1, Article 1. Available at: <https://scholarworks.sfasu.edu/raise/vol1/iss1/2>
- 141 Marsch, L. A., Moore, S. K., Grabinski, M., Bessen, S. Y., Borodovsky, J., & Scherer, E. (2021). Evaluating the Effectiveness of a Web-Based Program (POP4Teens) to Prevent Prescription Opioid Misuse Among Adolescents: Randomized Controlled Trial. *JMIR public health and surveillance*, 7(2), e18487. <https://doi.org/10.2196/18487>
- 142 Schwinn, T. M., Schinke, S. P., Keller, B., & Hopkins, J. (2019). Two- and three-year follow-up from a gender-specific, web-based drug abuse prevention program for adolescent girls. *Addictive behaviors*, 93, 86–92. <https://doi.org/10.1016/j.addbeh.2019.01.010>
- 143 Newton, N.C., Teesson, M., Vogl, L.E. and Andrews, G. (2010), Internet-based prevention for alcohol and cannabis use: final results of the Climate Schools course. *Addiction*, 105: 749-759. <https://doi.org/10.1111/j.1360-0443.2009.02853.x>